Venous Thromboembolism Prophylaxis in Obstetric Patients

Area of Science:

• Obstetrics
• Hematology
• Pharmacology

Background:

• Venous thromboembolism (VTE), encompassing pulmonary embolism (PE) and deep vein thrombosis (DVT), is the primary cause of maternal mortality in developed nations.
• Physiological adaptations during pregnancy create a hypercoagulable state, significantly elevating VTE risk in obstetric patients.
• Current guidelines lack a validated VTE risk-assessment tool for pregnant individuals and consensus on prophylactic anticoagulant strategies.

Purpose of the Study:

• To review the pathophysiological mechanisms underlying the heightened VTE risk in pregnancy.
• To examine the existing literature on the efficacy and safety of pharmacologic prophylaxis for VTE in obstetric patients.
• To highlight the need for evidence-based risk stratification and treatment protocols for VTE prevention in this population.

Main Methods:

• Literature review of studies on coagulation changes during pregnancy.
• Analysis of research on prophylactic anticoagulant use in at-risk obstetric patients.
• Synthesis of data regarding VTE incidence, risk factors, and prevention strategies in the obstetric population.

Main Results:

• Pregnancy-induced hypercoagulability is a significant driver of VTE.
• Prophylactic anticoagulation shows potential in reducing VTE events in high-risk pregnant individuals.
• Deficiencies exist in validated risk assessment tools and standardized prophylactic protocols in the US.

Conclusions:

• Understanding pregnancy-related coagulation disturbances is crucial for VTE prevention.
• Pharmacologic prophylaxis is a key strategy to mitigate VTE risk in at-risk obstetric patients.
• Development of validated risk assessment tools and consensus guidelines is imperative for optimal VTE management in pregnancy.